Diabetes Care, Vol 12, Issue 9 649-652, Copyright © 1989 by American Diabetes Association

ARTICLES

Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy

PJ Dyck and PC O'Brien
Peripheral Neuropathy Research Laboratory, Mayo Clinic, Rochester, Minnesota 55905.

Use of nerve conduction in assessing therapy in preventing or ameliorating neuropathy is desirable because abnormalities of nerve conduction are associated with severity of neuropathic symptoms and deficits. Assuming that a therapy is associated with a statistically significant improvement of nerve conduction, what degree of nerve conduction change is clinically meaningful? We suggest that in controlled clinical trials, a mean change of 2 points on the neurologic disability score is clinically detectable and meaningful. Based on our previously published cross-sectional epidemiological data, this corresponds to a change of motor nerve conduction velocity of the average ulnar median and peroneal nerves of 2.9 m/s and peroneal nerve of 2.2 m/s. The corresponding changes of amplitude were 1.2 and 0.7 mV, respectively. Smaller degrees of nerve conduction change were found when only insulin-dependent patients were evaluated.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. W. Albers, W. H. Herman, R. Pop-Busui, C. L. Martin, P. Cleary, B. Waberski, and for the Diabetes Control and Complications Trial ( Subclinical Neuropathy Among Diabetes Control and Complications Trial Participants Without Diagnosable Neuropathy at Trial Completion: Possible predictors of incident neuropathy? Diabetes Care, October 1, 2007; 30(10): 2613 - 2618. [Abstract] [Full Text] [PDF]

				J W Albers, D H Garabrant, S J Schweitzer, R P Garrison, R J Richardson, and S Berent The effects of occupational exposure to chlorpyrifos on the peripheral nervous system: a prospective cohort study Occup. Environ. Med., March 1, 2004; 61(3): 201 - 211. [Abstract] [Full Text] [PDF]

				K. R. Sharma, J. Cross, O. Farronay, D. R. Ayyar, R. T. Shebert, and W. G. Bradley Demyelinating Neuropathy in Diabetes Mellitus Arch Neurol, May 1, 2002; 59(5): 758 - 765. [Abstract] [Full Text] [PDF]

				D. R. Cornblath, V. Chaudhry, K. Carter, D. Lee, M. Seysedadr, M. Miernicki, and T. Joh Total neuropathy score: Validation and reliability study Neurology, November 1, 1999; 53(8): 1660 - 1660. [Abstract] [Full Text]

				C. M. Akbari, G. W. Gibbons, G. M. Habershaw, F. W. LoGerfo, and A. Veves The Effect of Arterial Reconstruction on the Natural History of Diabetic Neuropathy Arch Surg, February 1, 1997; 132(2): 148 - 152. [Abstract] [PDF]

				P. Reichard, B.-Y. Nilsson, and U. Rosenqvist The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes Mellitus N. Engl. J. Med., July 29, 1993; 329(5): 304 - 309. [Abstract] [Full Text]